[1] BARTALENA L,PIANTANIDA E,GALLO D,et al.Epidemiology,natural history,risk factors,and prevention of Graves' orbitopathy[J].Front Endocrinol (Lausanne),2020,11:615993.
[2] 中华医学会内分泌学分会,中国医师协会内分泌代谢科医师分会,中华医学会核医学分会,等.中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J].国际内分泌代谢杂志,2022,42(5):401-450.
[3] NIE T,LAMB Y N.Teprotumumab:a review in thyroid eye disease[J].Drugs,2022,82(17):1663-1670.
[4] GREENHILL C.Use of teprotumumab in thyroid eye disease[J].Nat Rev Endocrinol,2021,17(7):383.
[5] MARKHAM A.Teprotumumab:first approval[J].Drugs,2020,80(5):509-512.
[6] HAI Y P,LEE A C H,FROMMER L,et al.Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy[J].J Endocrinol Invest,2020,43(2):123-137.
[7] 汤进,黄晓霞,孔花娟,等.TSH、TPOAb、TRAb、TGAb检测在甲状腺疾病临床诊断中的应用研究[J].现代医学,2019,47(7):847-850.
[8] CUI X,WANG F,LIU C.A review of TSHR-and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy[J].Front Immunol,2023,14:1062045.
[9] SMITH T J.Thyroid-associated ophthalmopathy:emergence of teprotumumab as a promising medical therapy[J].Best Pract Res Clin Endocrinol Metab,2020,34(1):101383.
[10] DIANA T,PONTO K A,KAHALY G J.Thyrotropin receptor antibodies and Graves' orbitopathy[J].J Endocrinol Invest,2021,44(4):703-712.
[11] SMITH T J,JANSSEN J.Insulin-like growth factor-Ⅰ receptor and thyroid-associated ophthalmopathy[J].Endocr Rev,2019,40(1):236-267.
[12] KRIEGER C C,SUI X,KAHALY G J,et al.Inhibition of TSH/IGF-1 receptor crosstalk by Teprotumumab as a treatment modality of thyroid eye disease[J].J Clin Endocrinol Metab,2022,107(4):e1653-e1660.
[13] FERNANDO R,SMITH T J.Teprotumumab divergently alters fibrocyte gene expression:implications for thyroid-associated ophthalmopathy[J].J Clin Endocrinol Metab,2022,107(10):e4037-e4047.
[14] FERNANDO R,CALDERA O,SMITH T J.Therapeutic IGF-Ⅰ receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy[J].Proc Natl Acad Sci U S A,2021,118(52):e2114244118..
[15] CHEN H,MESTER T,RAYCHAUDHURI N,et al.Teprotumumab,an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes[J].J Clin Endocrinol Metab,2014,99(9):E1635-E1640.
[16] JANSSEN J,SMITH T J.Lessons learned from targeting IGF-Ⅰ receptor in thyroid-associated ophthalmopathy[J].Cells,2021,10(2):383.
[17] PHILIPPOU A,CHRISTOPOULOS P F,KOUTSILIERIS D M.Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer[J].Mutat Res Rev Mutat Res,2017,772:105-122.
[18] ZHOU H,MASCELLI M A.Mechanisms of monoclonal antibody-drug interactions[J].Annu Rev Pharmacol Toxicol,2011,51:359-372.
[19] XIN Y,XU F,GAO Y,et al.Pharmacokinetics and exposure-response relationship of teprotumumab,an insulin-like growth factor-1 receptor-blocking antibody,in thyroid eye disease[J].Clin Pharmacokinet,2021,60(8):1029-1040.
[20] U.S.Food and Drug Administration.TEPEZZA (teprotumumab-trbw) for injection,for intravenous use[EB/OL].[2023-11-20].https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf
[21] BURCH H B,PERROS P,BEDNARCZUK T,et al.Management of thyroid eye disease:a consensus statement by the American Thyroid Association and the European Thyroid Association[J].Eur Thyroid J,2022,11(6):e220189.
[22] SISTI E,COCO B,MENCONI F,et al.Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage:an epidemiological study[J].Eur J Endocrinol,2015,172(3):269-276.
[23] GENERE N,STAN M N.Current and emerging treatment strategies for Graves' orbitopathy[J].Drugs,2019,79(2):109-124.
[24] KURZROCK R,PATNAIK A,AISNER J,et al.A phase Ⅰ study of weekly R1507,a human monoclonal antibody insulin-like growth factor-I receptor antagonist,in patients with advanced solid tumors[J].Clin Cancer Res,2010,16(8):2458-2465.
[25] SMITH T J,KAHALY G J,EZRA D G,et al.Teprotumumab for thyroid-associated ophthalmopathy[J].N Engl J Med,2017,376(18):1748-1761.
[26] DOUGLAS R S,KAHALY G J,PATEL A,et al.Teprotumumab for the treatment of active thyroid eye disease[J].N Engl J Med,2020,382(4):341-352.
[27] DOUGLAS R S,KAHALY G J,UGRADAR S,et al.Teprotumumab efficacy,safety,and durability in longer-duration thyroid eye disease and re-treatment:OPTIC-X study[J].Ophthalmology,2022,129(4):438-449.
[28] UGRADAR S,SHI L,WANG Y,et al.Teprotumumab for non-inflammatory thyroid eye disease (TED):evidence for increased IGF-1R expression[J].Eye (Lond),2021,35(9):2607-2612.
[29] OZZELLO D J,KIKKAWA D O,KORN B S.Early experience with teprotumumab for chronic thyroid eye disease[J].Am J Ophthalmol Case Rep,2020,19:100744.
[30] OZZELLO D J,DALLALZADEH L O,LIU C Y.Teprotumumab for chronic thyroid eye disease[J].Orbit,2022,41(5):539-546.
[31] UGRADAR S,KANG J,KOSSLER A L,et al.Teprotumumab for the treatment of chronic thyroid eye disease[J].Eye (Lond),2022,36(8):1553-1559.
[32] DINIZ S B,COHEN L M,ROELOFS K A,et al.Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population[J].Ophthalmic Plast Reconstr Surg,2021,37(6):583-591.
[33] SEARS C M,WANG Y,BAILEY L A,et al.Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy:a multicenter study[J].Am J Ophthalmol Case Rep,2021,23:101111.
[34] CHIOU C A,RESHEF E R,FREITAG S K.Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease:a report of two cases[J].Am J Ophthalmol Case Rep,2021,22:101075.
[35] SLENTZ D H,SMITH T J,KIM D S,et al.Teprotumumab for optic neuropathy in thyroid eye disease[J].JAMA Ophthalmol,2021,139(2):244-247.
[36] HWANG C J,NICHOLS E E,CHON B H,et al.Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab[J].Eur J Ophthalmol,2022,32(3):Np46-Np49.
[37] CHENG O T,SCHLACHTER D M.Teprotumumab in advanced reactivated thyroid eye disease[J].Am J Ophthalmol Case Rep,2022,26:101484.
[38] KAHALY G J,DOUGLAS R S,HOLT R J,et al.Teprotumumab for patients with active thyroid eye disease:a pooled data analysis,subgroup analyses,and off-treatment follow-up results from two randomised,double-masked,placebo-controlled,multicentre trials[J].Lancet Diabetes Endocrinol,2021,9(6):360-372.
[39] AMARIKWA L,MOHAMED A,KIM S H,et al.Teprotumumab-related hyperglycemia[J].J Clin Endocrinol Metab,2023,108(4):858-864.
[40] KAY-RIVEST E,BELINSKY I,KOZLOVA A,et al.Prospective assessment of otologic adverse events due to teprotumumab:preliminary results[J].Otolaryngol Head Neck Surg,2023,168(5):1164-1169.
[41] LI H,YANG L,SONG Y,et al.Comparative effectiveness of different treatment modalities for active,moderate-to-severe Graves' orbitopathy:a systematic review and network Meta-analysis[J].Acta Ophthalmol,2022,100(6):e1189-e1198. |
